-
PNAS: Research progress on new molecules and pathways for epitranscriptional regulation of lysosome-mediated cell death
Time of Update: 2022-03-04
In this study, the researchers systematically identified gene expression profiles regulated by histone acetylation and found that histone deacetylase inhibitors can significantly induce LCDR expression and promote cancer cell survival by maintaining lysosomal integrity, This may be partly responsible for the adverse effects of acetylase drugs .
-
Clin Cancer Res: Efficacy of Olaparib (Olaparib) Monotherapy for Maintenance of Platinum-Sensitive Relapsed Ovarian Cancer in Asian Population: Phase III Clinical Study L-MOCA
Time of Update: 2022-03-04
Olaparib (olaparib) single-agent maintenance therapy improves PFS in patients with platinum-sensitive recurrent (PSR) ovarian cancer (OC) compared with placebo .
Olaparib (olaparib) single-agent maintenance therapy improves PFS in patients with platinum-sensitive recurrent (PSR) ovarian cancer (OC) compared with placebo .
-
Target Oncol: Real-world exploration of the efficacy of Crizotinib in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC)
Time of Update: 2022-03-04
Therefore, a team from the United States conducted a relevant real-world study to evaluate the efficacy of Crizotinib (crizotinib) in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) .
-
Molecular Cancer: An in situ dendritic cell tumor vaccine based on engineered exosomes for breast cancer treatment
Time of Update: 2022-03-04
Combination of cell-free exosome-based TLR3 agonists and ICD inducers provides a powerful and novel development platform for designing dendritic cell vaccines for breast cancer therapyCollectively, HELA-Exos developed in this study improved subsequent tumor-reactive CD8+ T cell responses by promoting in situ type 1 conventional dendritic cell (cDC1) activation in triple-negative breast cancer xenograft mice Demonstrated robust antitumor activity in models and human triple-negative breast cancer organoids .
-
"Body detox" turned out to be really reliable this time?
Time of Update: 2022-03-04
Physical activity preference in all men showed the best elimination potential for diformate and the worst for BaP (Fig.
Physical activity preference in all men showed the best elimination potential for diformate and the worst for BaP (Fig.
-
Med: Ketogenic diet enhances cancer treatment, prolongs survival
Time of Update: 2022-03-04
king of cancerRecently, the team of Joshua Rabinowitz of Princeton University (Yang Lifeng from Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences is the first author) published a research paper entitled: Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth in Med, a journal of Cell .
-
Lancet Oncol: Sugemalimab combined with platinum-based chemotherapy in first-line treatment of metastatic non-small cell lung cancer
Time of Update: 2022-03-04
6 months as of June 8, 2020 (interim analysis), median progression-free survival was significantly longer in the sugelimumab group compared with the placebo group (7.
-
Clin Cancer Res: A new treatment plan for locally advanced rectal cancer - preoperative chemoradiotherapy combined with nivolumab consolidation followed by radical surgery!
Time of Update: 2022-03-04
Consolidation therapy with nivolumab after preoperative chemoradiotherapy may improve the pathological complete response rate of locally advanced rectal cancer .
Consolidation therapy with nivolumab after preoperative chemoradiotherapy may improve the pathological complete response rate of locally advanced rectal cancer .
-
Int J Urol: How long should a patient be observed after radical prostatectomy?
Time of Update: 2022-03-04
Postoperative observation time was determined by investigating the risk rate of PSA failure and death from other causes using Weibull analysis observation timeThe study included 612 patients who underwent laparoscopic radical prostatectomy between June 2002 and December 2017 .
-
The new indication of "everolimus" was approved, and breast cancer treatment ushered in a new era of "endocrine +"
Time of Update: 2022-03-04
Good news for breast cancer patients: Novartis Afinitor® ( everolimus tablet) was recently approved by the State Drug Administration for a new indication, in combination with exemestane for the treatment of letrozole or anastrozole Hormone receptor-positive, epidermal growth factor receptor-2-negative, postmenopausal women with advanced breast cancer after failure .
-
NEJM: Cemiplimab for Recurrent Cervical Cancer
Time of Update: 2022-03-04
Survival was significantly longer with cemiplimab in patients with relapsed cervical cancer after first-line platinum-based chemotherapy than with continuation of single-agent chemotherapy .
Survival was significantly longer with cemiplimab in patients with relapsed cervical cancer after first-line platinum-based chemotherapy than with continuation of single-agent chemotherapy .
-
Eur Urol: Cancer control outcomes after local therapy with high-intensity focused ultrasound in patients with non-metastatic prostate cancer
Time of Update: 2022-03-04
Recently, researchers from the United Kingdom published an article in the journal Eur Urol reporting oncological outcomes and adverse events after high-intensity focused ultrasound (HIFU) treatment of non-metastatic prostate cancer .
-
Clin Cancer Res: Efficacy of olaparib maintenance monotherapy in Asian patients with platinum-sensitive recurrent ovarian cancer
Time of Update: 2022-03-04
Olaparib monotherapy maintenance therapy significantly prolongs progression-free survival (PFS) compared with placebo in patients with platinum-sensitive recurrent (PSR) ovarian cancer (OC) .
This study is the first to evaluate the efficacy and tolerability of olaparib in Asian patients with platinum-sensitive recurrent ovarian cancer .
-
Target Oncol: Prof. Wu Yilong's Phase IIIb study focuses on the efficacy of afatinib (afatinib) in the treatment of EGFR mutation-positive NSCLC patients in the near real world
Time of Update: 2022-03-04
Mainly to evaluate the efficacy of Afatinib (Afatinib) in the treatment of EGFRm+ NSCLC patients with EGFR-TKIs previously untreated in the near real world, with special attention to the efficacy of Chinese patients .
-
Radiology: Prostate MRI Fractal Analysis and PI-RADS in Prostate Cancer Grading
Time of Update: 2022-03-04
1007/s00330-021-08358-yFlorian Michallek Henkjan Huisman Bernd Hamm , et al Accuracy of fractal analysis and PI-RADS assessment of prostate magnetic resonance imaging for prediction of cancer grade groups: a clinical validation study 10.
-
Molecular Cell: Liu Ying's research group revealed a new mechanism of amino acid regulation of mTORC1 signaling pathway activity
Time of Update: 2022-03-04
On February 2, 2022, Liu Ying's research group from the Institute of Molecular Medicine, School of Future Technology, Peking University, Peking University-Tsinghua Life Science Joint Center, and Beijing Future Gene Diagnosis Advanced Innovation Center published an article entitled "E3 ligase RNF167 and deubiquitinase STAMBPL1 modulate mTOR and cancer progression”, reported the regulation mechanism of ubiquitin ligase RNF167 and deubiquitinase STAMBPL1 on mTORC1 and its important pathological significance .
-
NEJM: Trastuzumab Deruxtecan in metastatic HER2-mutant non-small cell lung cancer
Time of Update: 2022-03-04
Patients with HER2-mutated NSCLC have a slightly younger age of onset and a higher incidence of brain metastasesTrastuzumab deruxtecan (formerly DS-8201) is a HER2 antibody-drug conjugate whose efficacy and safety have not been extensively studied in patients with HER2-mutated NSCLC .
-
JAMA Neurol: SWI Manifestations of Intravascular Lymphoma
Time of Update: 2022-03-04
Intravascular lymphomas Intravascular lymphomas resemble cerebral microvascular lesions on MRI and include infarct-like lesions, white matter lesions, leptomeningeal enhancement, mass-like lesions, and hyperintense pontine lesions on sensitivity-weighted imaging (SWI) sequences may have higher sensitivityIn January 2022, Megan B.
-
Doctors top career rankings related to overall risk of prostate cancer!
Time of Update: 2022-03-04
81]) between overall PCa risk and specific occupations lasting 10 years or more (eg surveyors, draftsmen and related technicians ); medical, dental and veterinary work people (OR = 3.
-
European Radiology: Application of dual-energy CT in benign and malignant nasal lesions
Time of Update: 2022-03-04
Blood vesselRecently, a study published in the journal European Radiology explored the value of DECT in distinguishing benign and malignant sinus lesions by comparing simulated SECT, conventional MRI and DWI, and provided a reference for accurate diagnosis of sinus lesions .
